Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

NDAQ:VRTX) Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xeris Pharmaceuticals (XERS – Research Report), Quanterix ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that five therapeutic products containing molecules discovered ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Read here for highlights on Royalty Pharma's strategic updates, share repurchase program, and dividend increase with ...

The Food and Drug Administration has given Lupin a tentative nod for two new generics. The first medication is loteprednol etabonate ophthalmic gel, 0.38%, which is a generic of Bausch & Lomb’s ...